Trials / Terminated
TerminatedNCT02254044
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus With Repeated Administration Courses in Patients With Clinical Benefit
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bivatuzumab mertansine |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2004-11-01
- First posted
- 2014-10-01
- Last updated
- 2014-10-01
Source: ClinicalTrials.gov record NCT02254044. Inclusion in this directory is not an endorsement.